Navigation Links
Novation Supports New Development in the U.S. Biosimilar Pharmaceuticals Market
Date:8/30/2012

IRVING, Texas, Aug. 30, 2012 /PRNewswire/ -- Novation applauds the recent approval by the U.S. Food and Drug Administration of Sicor Biotech's tbo-filgrastim and the important milestone it represents in the continued development of biosimilar pharmaceuticals in the United States. Although approved through a full Biologics License Application and not a formal "biosimilar", this product is expected to fill the same role in clinical practice as subsequent biosimilars that are ultimately approved via the abbreviated pathway, signed into law in 2010. Sicor Biotech is expected to begin marketing tbo-filgrastim in November 2013.  

Biosimilars, which are 'highly similar' versions of reference biologics, are currently approved for use in the European Union and other regions. Research suggests that use of biosimilars could result in price decreases of 20 to 30 percent.

"Despite the slower pace of development in the U.S., biosimilars represent a much needed opportunity for lower-cost alternatives to commonly used biologics as hospitals struggle to contain drug related expenditures," said Steven Lucio, PharmD, BCPS, director of clinical solutions, pharmacy, Novation. "Both this product and subsequently approved biosimilars will require a great deal of physician, pharmacist and clinical staff education to ensure appropriate use and meaningful uptake in the US market. Novation is committed to serving as a resource to help healthcare providers prepare for biosimilars and maximize their impact."

The FDA approved Sicor's tbo-filgrastim as a treatment for patients receiving cancer chemotherapy who experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils.

Novation, the health care industry's leading supply contracting company for the members and affiliates of VHA Inc, UHC and Provista, has actively monitored the development process for biosimilars, and how biosimilars have progressed in Europe to identify keys issues for hospitals considering biosimilar therapies.    

Previously, Novation released a series of white papers, "Biosimilars – FDA Guidance Update," and "Preparing for Biosimilars," in 2011 and May 2012 to help hospitals and health care providers better understand the key components of the FDA's draft guidance and the potential impact of biosimilar usage as they gain broader adoption in the United States.

Please visit https://www.novationco.com/media/white_papers.asp for more information and to view the reports.

About Novation, Winner of the Ethics Inside® Certification

Founded in 1998, Novation is the leading health care supply chain expertise and contracting company for the more than 65,000 members of VHA Inc. and UHC, two national health care alliances, Children's Hospital Association, an alliance of the nation's leading pediatric facilities, and Provista, LLC. Novation provides alliance members with sourcing services, as well as information and data services. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 600 suppliers. VHA, UHC, and Provista members used Novation contracts to purchase more than $40 billion in 2011. Novation recently earned the coveted Ethics Inside® Certification from Ethisphere Institute, a leading international think tank dedicated to the research and promotion of best practices in corporate ethics and compliance.  Novation was also named on Ethisphere's World's Most Ethical Companies list, and is the only company in the health care industry to earn both distinctions.  To learn more about Novation, please visit www.novationco.com and follow @NovationNews.


'/>"/>
SOURCE Novation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cleveland Clinics 2012 Medical Innovation Summit Highlights Orthopaedic Technologies
2. Accelrys ELN Advances Innovation Lifecycle Management with Enhanced Biology Capabilities from Screening to Preclinical Development
3. U.S. Navy Awards Multi-Million Dollar Contract to Innovation for Pharmacy Automation Technologies
4. ImmusanT Relocates Offices to State-of-the-Art Innovation Facility
5. Center for Medicare & Medicaid Innovation Awards $19 Million Grant to Develop Oncology Medical Home Model
6. Elekta to Showcase Revolutionary Agility Beam-shaping Innovation at Radiation Physics Annual Meeting
7. Young Innovations, Inc. Board of Directors Declares Quarterly Dividend
8. Sanofi US Launches Collaborate Activate Innovation Challenge
9. Joslin Diabetes Center Convenes Leaders in Diabetes Prevention, Treatment, Payment, Education and Research at Diabetes Innovation 2012
10. Siemens Unveils New Solutions and Latest Innovations at AACC 2012
11. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):